Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus
Publication: Annals of Internal Medicine
Volume 141, Number 6
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
Abstract
Background:
In persons with diabetes, chronic hyperglycemia (assessed by glycosylated hemoglobin level) is related to the development of microvascular disease; however, the relation of glycosylated hemoglobin to macrovascular disease is less clear.
Purpose:
To conduct a meta-analysis of observational studies of the association between glycosylated hemoglobin and cardiovascular disease in diabetic persons.
Data Sources:
Search of the MEDLINE database by using Medical Subject Heading search terms and key words related to glycosylated hemoglobin, diabetes, and cardiovascular disease.
Study Selection:
Prospective cohort studies with data on glycosylated hemoglobin levels and incident cardiovascular disease.
Data Extraction:
Relative risk estimates were derived or abstracted from each cohort study that met the inclusion criteria.
Data Synthesis:
Adjusted relative risk estimates for glycosylated hemoglobin (total glycosylated hemoglobin, hemoglobin A1, or hemoglobin A1c levels) and cardiovascular disease events (coronary heart disease and stroke) were pooled by using random-effects models. Three studies involved persons with type 1 diabetes (n = 1688), and 10 studies involved persons with type 2 diabetes (n = 7435). The pooled relative risk for cardiovascular disease was 1.18; this represented a 1–percentage point increase in glycosylated hemoglobin level (95% CI, 1.10 to 1.26) in persons with type 2 diabetes. Results in persons with type 1 diabetes were similar but had a wider CI (pooled relative risk, 1.15 [CI, 0.92 to 1.43]).
Limitations:
This review largely reflects the limitations of the literature. Important concerns were residual confounding, the possibility of publication bias, the small number of studies, and the heterogeneity of study results.
Conclusions:
Pending confirmation from large, ongoing clinical trials, this analysis shows that observational studies are consistent with limited clinical trial data and suggests that chronic hyperglycemia is associated with an increased risk for cardiovascular disease in persons with diabetes.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34. [PMID: 9673301]
2.
Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care. 2001;24:1397-402. [PMID: 11473076]
3.
National Diabetes Data Group. Diabetes in America. 2nd ed. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995.
4.
Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81:1158-62. [PMID: 1951827]
5.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53. [PMID: 9742976]
6.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-86. [PMID: 8366922]
7.
Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med. 1998;158:134-40. [PMID: 9448551]
8.
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988;260:2864-71. [PMID: 3184351]
9.
Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996;124:90-6. [PMID: 8554220]
10.
Klein R, Klein BE, Moss SE, Cruickshanks KJ. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med. 1994;154:2169-78. [PMID: 7944837]
11.
Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23 Suppl 2 B21-9. [PMID: 10860187]
12.
Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H, et al . Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 2003;26 Suppl 1 S28-32. [PMID: 12502617]
13.
Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J (Clin Res Ed). 1983;287:867-70. [PMID: 6412862]
14.
Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, et al . High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360-7. [PMID: 9540016]
15.
Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-40. [PMID: 10333939]
16.
Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan DM, Peterson CM, et al . Tests of glycemia in diabetes. Diabetes Care. 2003;26 Suppl 1 S106-8. [PMID: 12502632]
17.
Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25:275-8. [PMID: 11815495]
18.
Meigs JB, Nathan DM, Cupples LA, Wilson PW, Singer DE. Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. J Clin Epidemiol. 1996;49:411-7. [PMID: 8621991]
19.
Rohlfing C, Wiedmeyer HM, Little R, Grotz VL, Tennill A, England J, et al . Biological variation of glycohemoglobin. Clin Chem. 2002;48:1116-8. [PMID: 12089188]
20.
Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002;48:436-72. [PMID: 11861436]
21.
Standards of medical care in diabetes. Diabetes Care. 2004;27 Suppl 1 S15-35. [PMID: 14693923]
22.
Golden S, Boulware L, Brancati F, Berkenblit G, Chander G, Marinopoulos S, et al . Use of glycated hemoglobin and microalbuminuria in the monitoring of diabetes mellitus. Evidence Report/Technology Assessment no. 84. Rockville, MD: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services; 2003.
23.
Fu CC, Chang CJ, Tseng CH, Chen MS, Kao CS, Wu TJ, et al . Development of macrovascular diseases in NIDDM patients in northern Taiwan. A 4-yr follow-up study. Diabetes Care. 1993;16:137-43. [PMID: 8422768]
24.
Florkowski CM, Scott RS, Moir CL, Graham PJ. Lipid but not glycaemic parameters predict total mortality from type 2 diabetes mellitus in Canterbury, New Zealand. Diabet Med. 1998;15:386-92. [PMID: 9609360]
25.
Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes. 1995;44:1303-9. [PMID: 7589828]
26.
Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hormann A, et al . Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia. 1996;39:1540-5. [PMID: 8960840]
27.
Lehto S, Ronnemaa T, Pyorala K, Laakso M. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb Vasc Biol. 1999;19:1014-9. [PMID: 10195930]
28.
Olson JC, Erbey JR, Forrest KY, Williams K, Becker DJ, Orchard TJ. Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. Metabolism. 2002;51:248-54. [PMID: 11833057]
29.
Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, et al . Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2003;26:1374-9. [PMID: 12716791]
30.
Lehto S, Ronnemaa T, Pyorala K, Laakso M. Risk factors predicting lower extremity amputations in patients with NIDDM. Diabetes Care. 1996;19:607-12. [PMID: 8725860]
31.
Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non–insulin-dependent diabetes. Stroke. 1996;27:63-8. [PMID: 8553405]
32.
Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 1997;46:1354-9. [PMID: 9231662]
33.
Moss SE, Klein R, Klein BE. The 14-year incidence of lower-extremity amputations in a diabetic population. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 1999;22:951-9. [PMID: 10372248]
34.
Kilpatrick ES, Rumley AG, Dominiczak MH, Small M. Glycated haemoglobin values: problems in assessing blood glucose control in diabetes mellitus. BMJ. 1994;309:983-6. [PMID: 7950717]
35.
Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1-30. [PMID: 3678409]
36.
Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non–insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke. 1994;25:1157-64. [PMID: 8202973]
37.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. [PMID: 3802833]
38.
Stata Statistical Software: Release 8.0. College Station, TX: Stata Corp; 2003.
39.
Adler AI, Neil HA, Manley SE, Holman RR, Turner RC. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). Am Heart J. 1999;138:S353-9. [PMID: 10539797]
40.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12. [PMID: 10938048]
41.
Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al . Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823-8. [PMID: 9549452]
42.
Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care. 2002;25:894-9. [PMID: 11978687]
43.
Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, et al . UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke. 2002;33:1776-81. [PMID: 12105351]
44.
Moss SE, Klein R, Klein BE, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med. 1994;154:2473-9. [PMID: 7979844]
45.
Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med. 1992;152:610-6. [PMID: 1546925]
46.
Moss SE, Klein R, Klein BE. Long-term incidence of lower-extremity amputations in a diabetic population. Arch Fam Med. 1996;5:391-8. [PMID: 8664997]
47.
Forrest KY, Becker DJ, Kuller LH, Wolfson SK, Orchard TJ. Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study. Atherosclerosis. 2000;148:159-69. [PMID: 10580182]
48.
Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. Coronary artery disease in IDDM. Gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol. 1996;16:720-6. [PMID: 8640398]
49.
Niskanen L, Turpeinen A, Penttila I, Uusitupa MI. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care. 1998;21:1861-9. [PMID: 9802734]
50.
Toyry JP, Niskanen LK, Mantysaari MJ, Lansimies EA, Uusitupa MI. Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis. Diabetes. 1996;45:308-15. [PMID: 8593935]
51.
Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non–insulin-dependent) diabetic and non-diabetic subjects. Diabetologia. 1993;36:1175-84. [PMID: 8270133]
52.
Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Am J Cardiol. 1997;80:164-9. [PMID: 9230153]
53.
Mattock MB, Barnes DJ, Viberti G, Keen H, Burt D, Hughes JM, et al . Microalbuminuria and coronary heart disease in NIDDM: an incidence study. Diabetes. 1998;47:1786-92. [PMID: 9792549]
54.
Roselli della Rovere G, Lapolla A, Sartore G, Rossetti C, Zambon S, Minicuci N, et al . Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr Metab Cardiovasc Dis. 2003;13:46-51. [PMID: 12772437]
55.
Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med. 2001;111:633-42. [PMID: 11755507]
56.
Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. Diabetes. 1982;31 Suppl 5 1-81. [PMID: 6757026]
57.
Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al . Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65. [PMID: 7797776]
58.
Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, et al . Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med. 1997;157:181-8. [PMID: 9009975]
59.
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-81. [PMID: 12020339]
60.
Feener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet. 1997;350 Suppl 1 SI9-13. [PMID: 9250277]
61.
Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288:2579-88. [PMID: 12444865]
62.
Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes. 1997;46 Suppl 2 S19-25. [PMID: 9285494]
63.
Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes. 1982;31:283-91. [PMID: 6818075]
64.
Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489-97. [PMID: 10082470]
65.
Libby P, Plutzky J. Diabetic macrovascular disease: the glucose paradox? [Editorial]. Circulation. 2002;106:2760-3. [PMID: 12450998]
66.
Wild SH, Dunn CJ, McKeigue PM, Comte S. Glycemic control and cardiovascular disease in type 2 diabetes: a review. Diabetes Metab Res Rev. 1999;15:197-204. [PMID: 10441042]
67.
Laakso M, Kuusisto J. Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in non–insulin-dependent diabetes mellitus. Ann Med. 1996;28:415-8. [PMID: 8949972]
68.
Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937-42. [PMID: 10331395]
69.
Donahue RP, Orchard TJ. Diabetes mellitus and macrovascular complications. An epidemiological perspective. Diabetes Care. 1992;15:1141-55. [PMID: 1396012]
70.
Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 2003;163:1306-16. [PMID: 12796066]
71.
Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, et al . Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294-303. [PMID: 12788993]
72.
de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, et al . Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999;42:926-31. [PMID: 10491751]
73.
Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al . Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001;322:15-8. [PMID: 11141143]
74.
Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study. Diabetes Care. 1996;19:450-6. [PMID: 8732708]
75.
Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25:1845-50. [PMID: 12351489]
76.
Harrell F, Conroy R. What are some of the problems with stepwise regression? Stata frequently asked questions. Accessed at www.stata.com/support/faqs/stat/stepwise.html on 17 June 2004
77.
Harrell FE. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
Information & Authors
Information
Published In
Annals of Internal Medicine
Volume 141 • Number 6 • 21 September 2004
Pages: 421 - 431
History
Published online: 21 September 2004
Published in issue: 21 September 2004
Keywords
Copyright
© 2004 American College of Physicians.
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus. Ann Intern Med.2004;141:421-431. [Epub 21 September 2004]. doi:10.7326/0003-4819-141-6-200409210-00007
Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus. Ann Intern Med.2004;141:421-431. [Epub 21 September 2004]. doi:10.7326/0003-4819-141-6-200409210-00007
View More
Login Options:
Purchase
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
Access to EPUBs and PDFs for FREE Annals content requires users to be registered and logged in. A subscription is not required. You can create a free account below or from the following link. You will be redirected to acponline.org to create an account that will provide access to Annals. If you are accessing the Free Annals content via your institution's access, registration is not required.
Create your Free Account
You will be redirected to acponline.org to create an account that will provide access to Annals.
Comments
0 Comments